The New England House
Best Food in the Area
Written by on February 6, 2017
Cancer Research Centers and Journals
We all know that cancer tops the list of primary medical problems in the universe. Cancer refers to a disease that commences as a renegade cell in the human body over which the human body has no control. To promote the proper and healthy functioning of the body, the cancer cells which overgrow must be regulated.
Even better, the cells must be separated from the active, useful cells to avoid replication. Currently, over 6.7 million people lose their lives to cancer annually. That is why medical practitioners and scientists have established cancer research institutes and journals to find therapies and treatments for cancer.
Oncotarget is an online journal in which articles on cancer treatment and therapies can be posted.
According to Research Gate, the primary objective of Oncotarget is to provide solutions for cancer treatment and prevention. In 2011, The Cancer Institute of National Research published an article on Oncotarget on conventional drugs and therapies for cancer.
The article addressed many of the questions linked to cancer cells and why they die in the deprivation of protein. Apparently, the protein, in this case, has an oncogene protein.
Mikhail’s Article on Oncotarget
The article also addressed the question of the possibility of extending patients lives by keeping the cancer tumors static. According to most medical practitioners, some cancers, known as disseminated cancers were cured by chemotherapy.
Dove Press revealed that the article addressed the issue by providing clear answers. Through Oncotarget, Mikhail Blagosklonny provided answers for most of the cancer questions. He posted the answers according to the questions presentation, through chapters. He combined all the issues and chose the most asked for answers.
About Mikhail Blagosklonny
Committed to finding therapies and cures for cancer and age treatment, Mikhail works at the Cancer Research Institute of Rosewell Park. He joined the department in December 2007 and has been a member and associate in the Oncology unit.
His research program focuses on many various elements of molecular biology as well as melanoma drug resistance. Mikhail is prominent for his TOR signaling hypothesis in aging as well as cancer treatment. He utilizes Oncotarget with the aim of creating cancer awareness including treatment and therapies.
Comments are closed.